Molecular and Clinical Oncology · 2013 · 13 citations · 10 references
MedicineGeriatric MedicineOncologyCancer EpidemiologyGeriatric PharmacotherapyThoracic OncologyCancer Epidemiology In Older AdultsCancer Survival AnalysisGeriatric OncologyLung CancerAge-specific Cancer RatesElderly PopulationErlotinib TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentObservational Study AnalysisObservational Study EvaluationOverall Mortality
The incidence and mortality of lung cancer have increased worldwide over the last decades, with an observed increased incidence particularly among elderly populations. It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non-small-cell lung cancer (NSCLC). The aim of this retrospective subgroup analysis of data from a population-based observational study was to assess the efficacy and safety of erlotinib in an elderly (≥75 years, n=74) and a younger group of patients (<75 years, n=233) who received treatment for NSCLC. The time to treatment failure was similar in the elderly [median, 62 days; 95% confidence interval (95% CI): 44-80 days] compared with the younger group (median, 46 days; 95% CI: 35-53 days) (P=0.2475). The overall survival did not differ between the elderly and younger groups (median, 170 days; 95% CI: 142-239 days vs. median, 146 days; 95% CI: 114-185 days, respectively) (P=0.7642). The adverse events did not differ in incidence between the groups and were manageable, regardless of age. Among the NSCLC patients receiving erlotinib treatment, the outcomes of the elderly (≥75 years) and younger (<75 years) groups of patients were similar in our population-based observational study.
10
Akira Inoue, Kunihiko Kobayashi, Kazuhiro Usui et al. · Journal of Clinical Oncology · 2009 · 516 citations
Medicine, Oncology, Pharmacology +13
Andrea Bezjak, Dongsheng Tu, Lesley Seymour et al. · Journal of Clinical Oncology · 2006 · 295 citations · Full text
Medicine, Oncology, Pharmacology +10
Makoto Maemondo, Yuji Minegishi, Akira Inoue et al. · Journal of Thoracic Oncology · 2012 · 157 citations
Medicine, Oncology, Pharmacotherapy +15
Federico Cappuzzo, Tudor–Eliade Ciuleanu, L. Stelmakh et al. · Journal of Clinical Oncology · 2009 · 125 citations
Medicine, Oncology, Pharmacology +13